Lifeward Ltd.
Close on Oct 19, 2026
- Market cap
- $16.58M
- P/E (TTM)
- –
- Dividend yield
- –
About Lifeward
Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842
Lifeward Ltd. develops, manufactures, and markets medical devices and robotic systems designed for physical rehabilitation, recovery, and mobility. Its product portfolio includes ReWalk Personal and Rehabilitation powered exoskeletons for individuals with spinal cord injuries and paraplegia, AlterG Anti-Gravity Systems for physical therapy and athletic training, and MyoCycle functional electrical stimulation cycles. The company also offers extended warranties, product leasing, maintenance services, and related consumable accessories. Its target customers comprise rehabilitation clinics, physical therapy centers, healthcare facilities, and individual end-users requiring personal mobility assistance.
The company operates internationally, serving customers across the United States, Europe, the Asia-Pacific region, and other global markets. Lifeward conducts development, quality management, and ReWalk product manufacturing in Israel, while utilizing third-party contract manufacturing for its AlterG products. The company maintains its principal executive offices in Hudson, Massachusetts, United States.
Summary of the business section of Lifeward's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Lifeward Ltd.
- Founded
- 2001
- Headquarters
- Hudson, MA
- Address
- 2 Cabot Road 01749
- Phone
- 15082511154
- Website
- golifeward.com
- Employees
- 81, Dec 31, 2025
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- KOST FORER GABBAY & KASIERER, Tel-Aviv, Israel
Stock & identifiers
- Ticker
- LFWD
- Exchange
- Nasdaq
- Shares outstanding
- 3M, Aug 12, 2026
- Public float
- $9.97M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Mar 18, 2026; 1-for-12 reverse, Feb 24, 2026; 1-for-7 reverse, May 15, 2024; 1-for-7 reverse, Mar 15, 2024; 1-for-25 reverse, May 8, 2019; 1-for-25 reverse, Apr 1, 2019
- SEC CIK
- 1607962
- CUSIP
- M8216Q309
- ISIN
- USM8216Q3094
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| William Mark Grant | President & CEO, Director | – |
| Lawrence J. Jasinski | Chief Executive Officer, Director | 100,870 |
| Keith Dale Rose | Chief Medical Officer | 17,083 |
| Almog Adar | Chief Financial Officer | 262,500 |
| Jeannine Lynch | VP of Market Access & Strategy | 142,134 |
| Haggai Zamir | Director | 6,711 |
| Yonason Greenwald | Director | 6,711 |
| Avraham Gabay | Director | 13,643 |
| Moshe H. Rozenbaum | Director | 11,485 |
| William Mark Sigsbee | Director | 11,485 |
| Nadav Kidron | Director | 7,657 |
| Miriam Kidron | Director | 7,657 |
| Yehuda Reznick | Director | 7,657 |
| Hadar Levy | Director | 51,576 |
| Michael Swinford | Director | 100,960 |
| John William Poduska Sr | Director | 55,953 |
| Robert J. Marshall Jr. | Director | 35,920 |
| Joseph E. Turk Jr | Director | 104,973 |
| Randel Richner | Director | 57,487 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Non Principal Executive Officer And Non Executive Officer | $437.86K | $393.15K | $437.86K | $11 | – |
| FY2025 PEOTwo | $834.87K | $620.78K | $437.86K | $11 | – |
| FY2025 Principal Executive Officer | $798.20K | $755.03K | $437.86K | $11 | – |
| FY2024 Larry Jasinski | $473.27K | $278.82K | $367.00K | $33 | – |
| FY2024 Non Principal Executive Officer And Non Executive Officer | $367.00K | $254.09K | $367.00K | $33 | – |
| FY2024 PEOTwo | $0 | $0 | $367.00K | $33 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 81 employees (including full-time and”
Corporate history
Events identified from SEC filings